secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2026-06-17T20:01:15+00:00
Accession:  0001453687-26-000090
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Cartesian Therapeutics shareholders elect three Class I directors, approve say-on-pay and auditor
--------------------------------------------------------------------------------

- Michael Singer, Timothy Springer, and Patrick Zenner elected Class I directors through 2029.
- Non-binding advisory vote on named executive officer compensation approved (13.7M for, 136K against).
- Ratification of Ernst & Young as independent auditor for FY2026 approved (24.1M for).
- Approximately 82.42% of outstanding shares represented at June 12, 2026 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000145368726000090/0001453687-26-000090-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000145368726000090/rnac-20260612.htm
  HTML page:      https://secwatch.observer/filing/0001453687-26-000090

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer